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A B S T R A C T
Background: We previously reported a cross-sectional analysis regarding the relationship between
smoking and atrial ﬁbrillation (AF) in a single hospital-based cohort with Japanese patients, but the effect
of cessation of smoking and/or total tobacco consumption were unclear.
Methods and results: We used data from the Shinken Database 2004–2011 (men/women, n = 10,714/
6803, respectively), which included all new patients attending the Cardiovascular Institute between June
2004 and March 2012. After excluding those previously diagnosed with AF (n = 2296), 15,221 patients
(men/women, n = 9016/6205) were analyzed. During the follow-up period of 2.0  2.1 years (range 0.0–
8.1), the incidence rates of new AF in smokers and non-smokers were 9.0 and 5.0 per 1000 patient-years,
respectively. In adjusted models with Cox regression analysis, smokers were independently associated with
new AF [hazard ratio (HR) 1.47, 95% conﬁdence interval (CI) 1.09–2.00]. Also, current smokers (HR 1.81, 95%
CI 1.17–2.79) and smokers with Brinkman index 800 (HR 1.69, 95% CI 1.05–2.70) were independently
associated with new AF. However, in current smokers, the HRs were not different by Brinkman index
(Brinkman index <800/800; HR 1.81/1.82, 95% CI 1.07–3.05/0.94–3.51, respectively).
Conclusions: Smoking was independently associated with the ﬁrst-appearance of AF in patients in sinus
rhythm, especially when the patients continued their smoking habit. However, in patients who
continued smoking, difference by total tobacco consumption was not observed, suggesting the
signiﬁcance of cessation of smoking for preventing AF. Our data are limited because of a single hospital-
based nature and a relatively short observation period.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Atrial ﬁbrillation (AF) is the most common arrhythmia
diagnosed in developed countries and is strongly associated
with an increase in cardiovascular mortality and morbidity
[1–5]. Several studies have noted that the prevalence of AF is
expected to substantially increase in the future because of the rise* Corresponding author at: Department of Cardiovascular Medicine, The
Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo 106-0031, Japan.
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0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsin age of society [6–8]. Primary prevention of AF is therefore of
great interest. This would require appropriate identiﬁcation of
people at high risk of developing AF. Risk factors for AF include
hypertension, type 2 diabetes, obesity, metabolic syndrome, and
chronic kidney disease [9–15], which are overlapping risk factors
for a number of cardiovascular diseases including coronary artery
disease [16–19].
Tobacco smoking is a well-known risk factor for cardiovascular
disease [20,21]. Smoking causes endothelial dysfunction and
atherosclerosis [22–25], and also can cause cardiac arrhythmias
[26] through the combined effects of nicotine, carbon monoxide,
and polycyclic aromatic hydrocarbons. These studies indicate that
tobacco smoking may accelerate atrial remodeling, contributing to reserved.
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reported the onset of AF following ingestion of nicotine [27,28],
the results of population-based studies examining the association
between smoking and AF are conﬂicting. In several cohort studies,
the effect of smoking on incidence of AF was not independent
[29–33], while recent large-scale cohort studies with longer-term
follow-up periods have demonstrated that smoking is indepen-
dently associated with the development of AF [34,35].
To date, there has been only a cross-sectional study published
on the association between smoking and AF in a Japanese context,
which we reported previously [36]. In this cross-sectional analysis,
we demonstrated that smoking habit was independently associat-
ed with the prevalence of AF. Notably, although signiﬁcant
interaction between smoking and sex category was observed
apparently in the effect of smoking on AF, it was assumed that it
was derived from an obvious difference of the distribution of
smokers by sex category; women smokers were younger and it
might weaken the effect of smoking in women. After adjustment
for age and other covariates, interaction between smoking and sex
category was diminished. However, we could not make it clear
whether cessation of smoking and/or total tobacco consumption
were associated with new incidence of AF. It should be ascertained
in a longitudinal cohort. Therefore, we analyzed the relationship
between smoking habit and the incidence of new AF in a hospital-
based cohort in an urban area of Japan (Shinken Database) [37–40]
with a longitudinal study design, considering the difference of
details regarding smoking habits.
Methods
Study participants
The Shinken Database, which was established in June 2004,
contains data on all new patients attending the Cardiovascular
Institute Hospital in Tokyo, Japan (abbreviated in Japanese as
‘Shinken’), excluding foreign travelers and patients with active
cancer. The principle aim of establishing this hospital-based
database is to monitor the prevalence and prognosis of cardiovas-
cular diseases in urban areas of Japan [37–40]. Data on patients’
health status and incidence of cardiovascular events and mortality
are linked with hospital medical records and data collected
through a postal survey repeated approximately once or twice
annually.
The data used in this study were derived from records from
17,517 new patients between June 2004 and March 2012 (Shinken
Database 2004–2011). Excluding 2296 patients who were diag-
nosed with AF at the initial visit, 15,221 patients were analyzed.
Data collection at initial visit
After obtaining an electrocardiogram and chest X-ray, patients’
cardiovascular statuses were evaluated using echocardiography,
an exercise test, 24-h Holter recordings, and blood laboratory data
from the initial visit. In addition to gender, age, height, and weight,
we collected data on cardiovascular diseases, including heart
failure (New York Heart Association class  2), valvular heart
disease (moderate or severe stenosis or regurgitation using
echocardiography), coronary heart disease (diagnosed by angiog-
raphy or scintigraphy), hypertrophic and dilated cardiomyopathy
(diagnosed by echocardiography or magnetic resonance imaging),
and history of a disabling cerebral infarction or transient ischemic
attack (diagnosed by computed tomography or magnetic reso-
nance imaging). Cardiovascular risk factors are deﬁned as follows:
hypertension (use of antihypertensive agents, systolic blood
pressure of  140 mmHg, or diastolic blood pressure  90 mmHg),
mmHg), diabetes mellitus (use of oral hypoglycemic agents orinsulin, or glycosylated hemoglobin  6.5%), dyslipidemia (use of
statin or drugs for lowering triglyceride, low-density lipopro-
tein  140 mg/dL, high-density lipoprotein < 40 mg/dL, or trigly-
ceride  150 mg/dL), chronic kidney disease (estimated glomerular
ﬁltration rate <60 ml/min/m2), and chronic obstructive pulmonary
disease. Metabolic syndrome (modiﬁed) was deﬁned as body mass
index (BMI) 25 kg/m2 and two or more of the following:
hypertension, diabetes mellitus, and dyslipidemia, because we do
not have data for abdominal circumference and/or full data for blood
pressure, blood sugar, and triglycerides. Information on medical
drugs included use of statins, renin–angiotensin system inhibi-
tors, anticoagulants, and antiplatelets. BMI was calculated as
weight in kilograms divided by height in meters squared. The
glomerular ﬁltration rate was estimated using the Japanese
coefﬁcient for the modiﬁed isotope dilution mass spectrometry
(IDMS)-traceable four-variable Modiﬁcation of Diet in Renal
Disease (MDRD) study equation (glomerular ﬁltration rate =
194  serum creatinine1.004  Age0.287  0.739 [if female])
[41].
Deﬁnition of AF
AF at the initial visit was diagnosed by electrocardiographic
recordings, including 12-lead surface electrocardiograms and 24-h
Holter recordings. It was also diagnosed by any medical history of
AF from referring physicians.
The ﬁrst-time appearance of AF was determined by electrocar-
diogram recorded during visits to the outpatient clinic and
inpatient stay at our hospital.
Categorization of smoking habits
In the present study, the principal categorization regarding
smoking habits was smokers and non-smokers. Next, smokers
were separated into former and current smokers. Also, smokers
were separated by a Brinkman index. A Brinkman index is an
estimation of a lifetime tobacco consumption of each smoker
before the initial visit to our hospital which was expressed as the
total count of cigarettes-years.
Statistical analysis
All analyses were performed using SPSS version 19.0 (SPSS Inc.,
Chicago, IL, USA). The level of statistical signiﬁcance was set at
p < 0.05. First, patient backgrounds were compared between
smokers and non-smokers, and in smokers, between former and
current smokers. The differences of categorical and consecutive
variables were tested by unpaired t-test and chi-squared test,
respectively. Furthermore in smokers, patient backgrounds were
compared between different levels of Brinkman index: <400, 400–
799, 800, and unknown. Unknown was insufﬁcient data which
could not be used to calculate Brinkman index.
Next, the incidence rates of new AF in each category of smoking
habit were calculated by person-year methods.
Finally, to identify the risk of smoking habits on incidence of AF,
unadjusted and adjusted models with Cox regression analysis were
determined. In these analyses, four types of parameters regarding
smoking habits were evaluated, which were smokers, cessation
status (current and former smokers), total tobacco consumption
(Brinkman index <400, 400–799, 800, and unknown), and
combination of cessation status and total tobacco consumption
[current and former, and Brinkman index of <800 (or unknown)
and 800, respectively]. These smoking habit-related parameters
were analyzed in different multivariate models, where they were
adjusted for all patient backgrounds (except for anticoagulants and
antiplatelets) by stepwise methods.
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Results
Characteristics of the study participants
Table 1 summarizes the baseline clinical characteristics of the
study population. Our population included 10,223 non-smokers
and 4988 smokers. Age was signiﬁcantly higher in smokers,
especially deriving from the high prevalence in the category of
50–69 years. Smokers had high prevalence of obesity (BMI 25),
hypertension, diabetes mellitus, and dyslipidemia, and conse-
quently had a high prevalence of modiﬁed metabolic syndrome.
Smoking was associated with high prevalence of coronary heart
disease, but less prevalence of valvular heart disease.
Current smokers had higher tobacco consumption, but were
associated with younger age and less prevalence of modiﬁed
metabolic syndrome, heart failure, valvular, and coronary heart
disease compared with former smokers.
Table 2 displays the patient backgrounds separated by levels of
total tobacco consumption. Age, BMI, the prevalence of hyperten-
sion, diabetes mellitus, dyslipidemia, modiﬁed metabolic syn-
drome, heart failure, and coronary heart disease clearly increased
according to increment of Brinkman index.
Difference in incidence rate of new AF according to smoking habits
During the follow-up period of 2.0  2.1 years (range 0.0–8.1),
new AF occurred in 77 smokers and 113 non-smokers with incidenceTable 1
Baseline characteristics of patients from the Shinken Database 2004–2011, Tokyo, Japa
Variable Non-smokers
(n = 10,223)
Smokers
(n = 4988)
Age (years) 56.5  16.5 57.0  13.
BMI (kg/m2) 23.0  3.7 24.0  3.6
Cigarette-years – 570.7  500
Age <30 710 (6.9) 154 (3.1) 
30–49 2527 (24.7) 1255 (25.2) 
50–69 4581 (44.8) 2653 (53.2) 
70 2415 (23.6) 926 (18.6) 
Men 4982 (48.7) 4034 (80.9) 
BMI 25 kg/m2 2384 (23.3) 1788 (35.8) 
Hypertension 3417 (33.4) 2177 (43.6) 
Diabetes mellitus 1063 (10.4) 835 (16.7) 
Dyslipidemia 2691 (26.3) 1836 (36.8) 
Metabolic syndrome (modiﬁed)a 717 (7.0) 733 (14.7) 
Heart failure 628 (6.1) 327 (6.6) 
Valvular heart disease 759 (7.4) 308 (6.2) 
Coronary heart disease 1465 (14.3) 1195 (24.0) 
Hypertrophic cardiomyopathy 136 (1.3) 100 (2.0) 
Dilated cardiomyopathy 98 (1.0) 71 (1.4) 
Cerebral infarction or transient ischemic attack 189 (1.8) 175 (3.5) 
Chronic kidney disease 1395 (13.6) 781 (15.7) 
Chronic obstructive pulmonary disease 33 (0.3) 60 (1.2) 
Anemia (hemoglobin <11 g/dL) 399 (3.9) 139 (2.8) 
Hyperthyroidism 37 (0.4) 35 (0.7) 
Statin use 1438 (14.1) 1095 (22.0) 
Renin–angiotensin system inhibitors use 1848 (18.1) 1255 (25.2) 
Anticoagulant use 539 (5.3) 261 (5.2) 
Antiplatelet use 2160 (21.1) 1528 (30.6) 
Categorical and continuous variables are presented as numbers (%) and mean  stand
calculated by unpaired t-test and chi-square test, respectively.
BMI, body mass index.
a Metabolic syndrome (modiﬁed) was deﬁned as BMI 25 kg/m2 and two or more orates of 9.0 and 5.0 per 1000 patient-years (95% CI 4.2–6.0 and 7.2–
11.3), respectively (Table 3). Among smokers, the incidence rate of
new AF in current smokers was 9.8 per 1000 patient-years (95% CI
6.7–14.2) which was higher than that in former smokers with an
incidence rate of 8.6 per 1000 patient-years (95% CI 6.5–11.4). Also,
the incidence rate of new AF in smokers with Brinkman index 800
was 10.6 per 1000 patient-years (95% CI 7.0–15.9) which was higher
than that in those with Brinkman index <400 and 400–799 with
incidence rates of 8.2 and 8.7 per 1000 patient-years (95% CI 5.4–12.4
and 5.8–13.0, respectively).
Risk evaluation of smoking habits on incidence of AF
To evaluate the risk of having smoking habit on incidence of AF,
unadjusted and adjusted Cox regression analyses were performed
(Table 4). The unadjusted hazard ratio (HR) for incidence of AF
indicated a signiﬁcant effect of smokers (HR 1.63; 95% CI, 1.22–
2.18; p = 0.001). Even after adjustment for various cofactors, the
effect of smoking on AF remained independent (HR 1.47; 95% CI,
1.08–2.00; p < 0.001). When smokers were separated into former
and current smokers, current smokers were signiﬁcantly associat-
ed with incidence of AF in unadjusted model (HR 1.74; 95% CI,
1.14–2.65; p = 0.009), and also independently associated with it in
adjusted model (HR 1.81; 95% CI, 1.17–2.79; p = 0.007). Although
former smokers were apparently associated with incidence of AF,
independent association was not observed after adjustment for
various cofactors. When smokers were separated according to the
levels of Brinkman index, smokers with Brinkman index 800
were the only independent predictor for incidence of AF (HR 1.69;
95% CI 1.05–2.70; p = 0.028).
Furthermore, we separated the smokers by combined catego-
ries of smoking cessation (former and current) and total tobacco
consumption (Brinkman index <400 or unknown and 800). In then.
p-Value
(smokers vs.
non-smokers)
Former
(n = 3300)
Current
(n = 1688)
p-Value
(current vs.
former)
8 0.049 59.5  13.2 52.2  13.5 <0.001
 <0.001 24.0  3.5 24.0  3.8 0.539
.7 – 524.4  493.1 656.1  503.7 <0.001
<0.001 59 (1.8) 95 (5.6) <0.001
659 (20.0) 596 (35.3)
1823 (55.2) 830 (49.2)
759 (23.0) 167 (9.9)
<0.001 2672 (81.0) 1362 (80.7) 0.819
<0.001 1189 (36.0) 599 (35.5) 0.708
<0.001 1546 (46.8) 631 (37.4) <0.001
<0.001 562 (17.0) 273 (16.2) 0.471
<0.001 1245 (37.7) 591 (35.0) 0.063
<0.001 513 (15.5) 220 (13.0) 0.018
0.319 234 (7.1) 93 (5.5) 0.034
0.005 222 (6.7) 86 (5.1) 0.025
<0.001 820 (24.8) 375 (22.2) 0.042
0.002 61 (1.8) 39 (2.3) 0.286
0.012 46 (1.4) 25 (1.5) 0.802
<0.001 137 (4.2) 38 (2.3) <0.001
<0.001 608 (18.4) 173 (10.2) <0.001
<0.001 40 (1.2) 20 (1.2) 1.000
<0.001 99 (3.0) 40 (2.4) 0.237
0.005 20 (0.6) 15 (0.9) 0.283
<0.001 759 (23.0) 336 (19.9) 0.013
<0.001 896 (27.2) 359 (21.3) <0.001
<0.001 190 (5.8) 71 (4.2) <0.001
<0.001 1069 (32.4) 459 (27.2) <0.001
ard deviation, respectively. p-Values for continuous and categorical variables were
f the following three: hypertension, diabetes mellitus, and dyslipidemia.
Table 2
Baseline characteristics of patients with history of smoking habits separated by the total amount of cigarettes.
Variable Brinkman index
<400 (n = 1900) 400–799 (n = 1426) 800 (n = 1116) Unknown (n = 546) p-Value
Age (years) 50.8  14.5 58.7  11.7 63.6  9.7 61.1  14.1 <0.001
BMI (kg/m2) 23.4  3.7 24.4  3.4 24.6  3.5 23.9  3.4 <0.001
Cigarette-years 178.4  111.6 571.3  117.9 1238.0  501.8 – <0.001
Former smokers 530 (27.9) 544 (38.1) 488 (43.7) 126 (23.1) <0.001
Current smokers 1370 (72.1) 882 (61.9) 628 (56.3) 420 (76.9)
Age <30 140 (7.4) 4 (0.3) 0 (0.0) 10 (1.8) <0.001
30–49 750 (39.5) 323 (22.7) 86 (7.7) 96 (17.6)
50–69 818 (43.1) 827 (58.0) 738 (66.1) 270 (49.5)
70 192 (10.1) 272 (19.1) 292 (26.2) 170 (31.1)
Men 1342 (70.6) 1237 (86.7) 1048 (93.9) 407 (74.5) <0.001
BMI 25 kg/m2 542 (28.5) 594 (41.7) 463 (41.5) 189 (34.6) <0.001
Hypertension 599 (31.5) 675 (47.3) 638 (57.2) 265 (48.5) <0.001
Diabetes mellitus 166 (8.7) 260 (18.2) 315 (28.2) 94 (17.2) <0.001
Dyslipidemia 539 (28.4) 553 (38.8) 524 (47.0) 220 (40.3) <0.001
Metabolic syndrome (modiﬁed)a 179 (9.4) 225 (15.8) 249 (22.3) 80 (14.7) <0.001
Heart failure 78 (4.1) 89 (6.2) 102 (9.1) 58 (10.6) <0.001
Valvular heart disease 102 (5.4) 92 (6.5) 79 (7.1) 35 (6.4) 0.267
Coronary heart disease 291 (15.3) 337 (23.6) 407 (36.5) 160 (29.3) <0.001
Hypertrophic cardiomyopathy 30 (1.6) 32 (2.2) 31 (2.8) 7 (1.3) 0.071
Dilated cardiomyopathy 23 (1.2) 25 (1.8) 14 (1.3) 9 (1.6) 0.543
Cerebral infarction or transient ischemic attack 43 (2.3) 53 (3.7) 54 (4.8) 25 (4.6) <0.001
Chronic kidney disease 192 (10.1) 224 (15.7) 253 (22.7) 112 (20.5) <0.001
Chronic obstructive pulmonary disease 7 (0.4) 4 (0.3) 40 (3.6) 9 (1.6) <0.001
Anemia (hemoglobin <11 g/dL) 37 (1.9) 35 (2.5) 39 (3.5) 28 (5.1) <0.001
Hyperthyroidism 15 (0.8) 11 (0.8) 4 (0.4) 5 (0.9) 0.465
Statin use 279 (14.7) 343 (24.1) 331 (29.7) 142 (26.0) <0.001
Renin–angiotensin system inhibitors use 339 (17.8) 388 (27.2) 367 (32.9) 161 (29.5) <0.001
Anticoagulant use 77 (4.1) 62 (4.3) 88 (7.9) 34 (6.2) <0.001
Antiplatelet use 388 (20.4) 444 (31.1) 505 (45.3) 191 (35.0) <0.001
Categorical and continuous variables are presented as numbers (%) and mean  standard deviation, respectively.
BMI, body mass index.
a Metabolic syndrome (modiﬁed) was deﬁned as BMI 25 kg/m2 and two or more of the following three: hypertension, diabetes mellitus, and dyslipidemia.
Table 3
Incidence rates of atrial ﬁbrillation by smoking status categories.
Variable No. of events Person-years Incidence rate (per 1000 person-years) 95% conﬁdence interval
Total 190 31,107 6.1 5.3–7.0
Non-smoker 113 22,557 5.0 4.2–6.0
Smoker 77 8550 9.0 7.2–11.3
Former 50 5793 8.6 6.5–11.4
Current 27 2757 9.8 6.7–14.2
Brinkman index <400 22 2684 8.2 5.4–12.4
Brinkman index 400–799 23 2659 8.7 5.8–13.0
Brinkman index 800 23 2174 10.6 7.0–15.9
Brinkman index unknown 9 1033 8.7 4.6–16.6
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independently or tended to be associated with incidence of AF
with similar HRs: current smokers with Brinkman index <800 or
unknown and 800; HR 1.81 and 1.82; 95% CI 1.07–3.05 and 0.94–
3.51; p = 0.027 and 0.074, respectively).
Discussion
This study showed that smoking was independently associated
with incidence of AF among patients in a cardiovascular hospital in
an urban area of Japan. We previously reported [36] that smoking
habit was independently associated with the prevalence of AF after
adjustment for various cofactors, and the effect was not
signiﬁcantly affected by the interaction with sex category. In the
present study, we added information regarding the cessation of
smoking and the amount of total tobacco consumption in a
longitudinal manner. Among those with history of smoking,
cessation of smoking made a difference in the effect on new AF:although the effect of former smokers on new AF was diminished
after the adjustment for various cofactors, the effect of current
smokers was still independent in the full adjustment model.
Furthermore, although smokers were apparently associated with
new AF from low to high levels of total tobacco consumption, only
smokers with Brinkman index 800 were independently associ-
ated with new AF in the adjusted model. However, in current
smokers, the HR was mostly similar between low and high total
tobacco consumption.
In general, habitual tobacco use is highly prevalent in men, and
is one of the major causes of hypertension [42–44], chronic
obstructive pulmonary disease [45,46], and chronic kidney disease
[47–52]. And notably, these cofactors have been reported as
independent risk factors for development of AF [9–15,53,54]. Also,
smokers are linked to various worse patient proﬁles including
obesity, diabetes, and dyslipidemia, which consequently lead to
so-called metabolic syndrome [55,56]. Interestingly, these patient
proﬁles have also been identiﬁed as independent risk factors for
Table 4
Effect of smoking habits on incidence of atrial ﬁbrillation (longitudinal analysis with Cox regression models).
Variable Hazard ratio (95% CI) p-Value
Smokers (vs. non-smokers)
Non-adjusted 1.63 (1.22–2.18) 0.001
Adjusted 1.47 (1.08–2.00) 0.013
Current and former smokers (vs. non-smokers)
Non-adjusted
Former smokers 1.54 (1.10–2.16) 0.012
Current smokers 1.74 (1.14–2.65) 0.009
Adjusted
Former smokers 1.33 (0.94–1.89) 0.101
Current smokers 1.81 (1.17–2.79) 0.007
Smokers separated by total tobacco consumption (vs. non-smokers)
Non-adjusted
Smokers with Brinkman index <400 1.39 (0.88–2.20) 0.018
Smokers with Brinkman index 400–799 1.61 (1.03–2.53) 0.036
Smokers with Brinkman index 800 1.97 (1.26–3.09) 0.003
Smokers with Brinkman index unknown 1.61 (0.81–3.18) 0.166
Adjusted
Smokers with Brinkman index <400 1.41 (0.88–2.24) 0.148
Smokers with Brinkman index 400–799 1.42 (0.89–2.26) 0.133
Smokers with Brinkman index 800 1.69 (1.05–2.70) 0.028
Smokers with Brinkman index unknown 1.34 (0.67–2.67) 0.398
Smokers separated by total tobacco consumption (vs. non-smokers)
Non-adjusted
Former smokers with Brinkman index <800 or unknown 1.46 (1.01–2.13) 0.043
Former smokers with Brinkman index 800 1.96 (1.10–3.48) 0.021
Current smokers with Brinkman index <800 or unknown 1.64 (0.98–2.74) 0.056
Current smokers with Brinkman index 800 1.99 (1.04–3.81) 0.036
Adjusted
Former smokers with Brinkman index <800 or unknown 1.27 (0.86–1.86) 0.216
Former smokers with Brinkman index 800 1.58 (0.87–2.87) 0.128
Current smokers with Brinkman index <800 or unknown 1.81 (1.07–3.05) 0.027
Current smokers with Brinkman index 800 1.82 (0.94–3.51) 0.074
CI, conﬁdence intervals.
The hazard ratios and 95% conﬁdence intervals for the relationship between smoking habits (smokers, current and former smokers, smokers with various levels of total
tobacco consumption vs. non-smokers) and incidence of new atrial ﬁbrillation with Cox regression analysis are presented in non-adjusted and adjusted models.
In the adjusted models, the hazard ratios of each smoking habits status are adjusted for all other covariates in Tables 1 and 2 (except for anticoagulant and antiplatelet)
using the stepwise method.
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between smoking and AF might be partially explained by an
indirect linkage via these confounding factors. However, such an
indirect linkage only cannot fully explain the relationship between
smoking habits and AF in the present study, because the
relationship was independent in a multivariate model. This point
of view is just the same as that described in our previous report
with a cross-sectional design [36].
Several large-scale cohort studies with longer follow-up
periods have reported that smoking is an independent predictor
for the development of AF [34,35]. Our results in the present study
expanded these ﬁndings to a Japanese context. Notably in our
population, current smoking was independently associated with
AF incidence, while former smoking was not. In our patients, the
apparent effect of former smokers on AF was diminished by various
patient backgrounds, indicating strong cofounding effects between
smoking habits and various cardiovascular risks. However, the
independent effect of current smokers (in other words, patients
who continue smoking) on AF indicates some causal effects of
smoking. As we described previously [36], the causal relationship
between smoking and AF can be explained by several mechanisms.
Nicotine in cigarettes increases heart rate and blood pressure [59],
mainly as a consequence of increased plasma catecholamine
concentration due to nicotine stimulating sympathetic neuro-
transmission [60]. It is also reported that ion channel conduction in
atrial myocytes is altered by nicotine, which may increase
electrical instability and consequently lead to ﬁbrillation in atria.
Moreover, nicotine blocks the transient outward K+ current (Ito),
which may inﬂuence cardiac repolarization and membranetransport processes to increase electrical instability in atria
[61]. Studies using canine models suggest that cigarette smoke
may also induce proarrhythmic atrial ﬁbrosis via down-regulation
of atrial microRNAs in atrial ﬁbroblasts, alongside up-regulation of
transforming growth factors TGF-b1 and TGF-bRII [62–64].
It is assumed that, if a smoking-related remodeling in atrium
truly exists, the promotion of the remodeling depends on the
amount of the tobacco consumption. In the present study, patients
with Brinkman index 800 were independently associated with
incidence of new AF. However, when we simultaneously examined
the effect of smoking cessation category (current and former) and
total tobacco consumption (Brinkman index <400 or unknown and
800), although apparent difference was observed between the
Brinkman index categories in current smokers, the difference was
diminished after adjustment for various cofactors. It means that,
although atrial remodeling may have been higher in patients with
high tobacco consumption, the causes of remodeling were
multifactorial, including hypertension, obesity, and/or heart
failure, and the effects of smoking did not exceed the effects of
other risk factors, at least in our population. Meanwhile,
continuing smoking independently and strongly affected incidence
of AF with HR of 1.8, regardless of the levels of Brinkman index.
This independent association should be emphasized because the
current smokers in the present study were younger and had less
prevalence of various cardiovascular risk factors. The strong
association between current smoking and incidence of new AF was
consistent with a previous report from the ARIC study [35]. How-
ever, in the ARIC study, former smokers with Brinkman index 800
were also independently associated with incidence of new AF. In
S. Suzuki et al. / Journal of Cardiology 66 (2015) 73–7978this regard, our data might be lacking in the statistical power
presumably due to a relatively short observation period and a
small number of incident AF.
Study limitations
As was explained in the discussion, we failed to demonstrate
the relationship between tobacco consumption and the incidence
of AF in former smokers with inconsistent results from a previous
large cohort [35]. In this regard, more investigation with a longer
observation period will be necessary. Moreover, older patients
tend to have more severe cardiovascular diseases and/or risk
factors compared with younger patients when they start to visit a
cardiovascular hospital like ours, and they may quit or reduce the
amount of daily cigarettes after starting care in such a hospital.
Therefore, data from a longitudinal cohort in a cardiovascular
hospital like ours might underestimate the risk of smoking habits
compared with those in a general population [35]. The incidence of
AF was determined using patients’ medical histories and clinical
examinations using electrocardiograms and Holter recordings.
This diagnostic method is known to underestimate true occurrence
rate of AF, because of its low sensitivity for detecting asymptom-
atic AF [65]. Our database did not include sleep apnea [66,67] and
caffeine intake [68] so we did not evaluate the effect of these
cofactors in the multivariate models.
Conclusions
Smoking was independently associated with the ﬁrst-appear-
ance of AF in patients in sinus rhythm, especially when the patients
continued their smoking habit. However, in patients who
continued smoking, difference by total tobacco consumption
was not observed, suggesting the signiﬁcance of cessation of
smoking for preventing AF. Our data are limited because of the
single hospital-based nature and a relatively short observation
period.
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